Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1

LBA6 - UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells and epitope spreading in patients with advanced non-small cell lung cancer


08 Dec 2022


Mini Oral session 1



Tumour Site

Non-Small Cell Lung Cancer


Olivier Adotevi


Annals of Oncology (2022) 16 (suppl_1): 100104-100104. 10.1016/iotech/iotech100104


O. Adotevi1, C. Laheurte2, L. Boullerot3, M. Malfroy3, T. Richard4, L. Cuche5, E. Seffar4, M. Jacquin5, E. Orillard6, G. Eberst7, C. Jandus8, V. Westeel7, C. Borg7, Y. Godet4

Author affiliations

  • 1 UMR1098, 25020 - Besancon/FR
  • 2 Université de Bourgogne Franche Comté, 25020 - Besancon/FR
  • 3 Université de Bourgogne Franche Comté, Besancon/FR
  • 4 UMR1098, Besancon/FR
  • 5 Chu De Besancon, Besancon/FR
  • 6 University Hospital of Besancon, Besançon/FR
  • 7 CHRU Besancon - Hopital Jean Minjoz, 25030 - Besancon/FR
  • 8 University of Geneva - Faculty of Medicine, Geneva/FR


Login to access the resources on OncologyPRO.

Abstract LBA6


The stimulation of antitumor CD4 T helper response represents a critical requirement for therapeutic cancer vaccine effectiveness. In this context, we developed a Th1-inducer anticancer peptide vaccine derived from telomerase called UCPVax (Dosset et al. Clin Can Res 2012). The safety and efficacy of UCPVax therapeutic vaccination were recently reported in metastatic non-small cell lung cancer (NSCLC) phase I/II trial (Adotévi et al., J Clin Oncol 2022, NCT02818426). Here, we described the immunological responses promoted by UCPVax.


Immune monitoring was performed in 52 patients with refractory metastatic NSCLC previously vaccinated with three doses of UCPVax for six times (one per week) followed by boost every two months for one year. Blood samples were collected before and at different times after vaccination. Vaccine-specific CD4 T cell responses and epitope spreading were evaluated by IFN-γ ELISPOT assay. MHC class II pentamer staining and intracellular cytokine secretion assay were used for the assessment of phenotype function and polarization of antigen specific CD4 T cells. Vaccine induced antibody response was measured by ELISA.


Seventy % of patients mounted strong UCP-specific CD4 T cells after vaccination regardless the dose level. UCPVax induced de novo and strong UCP-specific CD4 T-cell response and the intensity of the response increased according to the number of vaccinations. The UCP-specific CD4 T cells were effector memory phenotype, showed cytotoxic potential and (IFN-γ,TNF-a, IL-2)+ Th1 polarization which were maintained in long-term responders. Increased level of antibody response against UCP was found in 45% of patients which was correlated to the number of UCP-CD4 T cells. Furthermore, UCPVax induced epitope spread responses against various tumor antigens in most of patients analyzed. Finally, patients displayed polyfunctional anti-UCP CD4 response and epitope spreading had a better survival.


UCPVax vaccination promotes highly functional and long-lasting tumor specific CD4 T cell responses associated with the improvement of patients’ survival.

Clinical trial identification


Legal entity responsible for the study

O. Adotevi.


National Cancer Institute INCa France PHRC program.


O. Adotevi: Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Non-Financial Interests, Personal, Principal Investigator: MSD. V. Westeel: Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Speaker’s Bureau: Amgen, Lilly, MSD, BMS. C. Borg: Financial Interests, Personal, Advisory Role: MSD Oncology, Roche; Financial Interests, Institutional, Sponsor/Funding: Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.